Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 2:35 p.m. EDT. The presentation will be webcast live, with a replay available in the Events & Presentations section of the company's investor relations website. This engagement provides a platform for Helus Pharma to discuss its clinical programs and strategic direction with investors and industry analysts.
The company is currently advancing two lead candidates: HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration; and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder (GAD). These programs target large unmet needs in mental health, aiming to provide durable improvements through activation of serotonin pathways that promote neuroplasticity. Helus Pharma's approach is supported by class-leading data, positioning it to potentially reshape the treatment landscape for depression and anxiety.
The Jefferies conference participation comes at a pivotal time for Helus Pharma, as it seeks to differentiate its pipeline from other psychedelic-inspired therapies. The company's proprietary NSAs are synthetic molecules designed to offer improved efficacy and safety profiles compared to traditional treatments. With HLP003 in late-stage trials and HLP004 advancing, the company is building momentum toward potential regulatory submissions. Investors and stakeholders can access the full press release for more details here. Additionally, company updates are available on the Helus Pharma newsroom here.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company's commitment to developing novel treatments for mental health conditions underscores the importance of its current clinical milestones. As the company prepares for the fireside chat, the event represents an opportunity to articulate its vision and progress to a global audience of healthcare investors.
